2.16Open1.70Pre Close10 Volume6 Open Interest25.00Strike Price2.13KTurnover61.99%IV6.65%PremiumSep 20, 2024Expiry Date0.41Intrinsic Value100Multiplier27DDays to Expiry1.69Extrinsic Value100Contract SizeAmericanOptions Type0.5805Delta0.0914Gamma13.03Leverage Ratio-0.0331Theta0.0094Rho7.56Eff Leverage0.0269Vega
Phreesia Stock Discussion
• $Okta (OKTA.US)$ +15.8% (In reaction to earnings)
• $StoneCo (STNE.US)$ +12.9% (In reaction to earnings)
• $Turning Point Therapeutics (TPTX.US)$ +116.8% (Bristol Myers Squibb (BMY) will acquire Turning Point Therapeutics for $76,00 per share; expected to be accretive to Non-GAAP earnings per share beginningin2025)
• $Amylyx Pharmaceuticals (AMLX.US)$ +24.9% (receives PDUFA date extension for AMX0035; scheduled for September ...
• $CDW Corp (CDW.US)$: Stifel Upgrades to Buy from Hold - PT $210 (from $200)
• $Corteva (CTVA.US)$ : Loop Capital Upgrades to Buy from Hold - PT $69
• $CoreCivic, Inc. (CXW.US)$ : Wedbush Upgrades to Outperform from Neutral - PT $17 (from $10.85)
• $Delta Air Lines (DAL.US)$ : Barclays Upgrades to Overweight from Equalweight - PT $60 (from $42)
• $H.B. Fuller (FUL.US)$ : Baird Upgrades to Outperform from Neutral - PT $85
• $Huntington Ingalls Industries (HII.US)$ : Cowen U...
• $Clovis Oncology (CLVS.US)$ +40.6% (Rubraca significantly improves progression-free survival in first-line maintenance treatment in women with ovarian cancer regardless of their biomarker status in phase 3 athena-mono trial)
• $Dare Bioscience (DARE.US)$ +13.61% (Organon and Dar Bioscience have entered into an agreement whereby Organon will license global rights to XACIATO)
• $KULR Technology (KULR.US)$ +9.5% (secured a battery sa...
No comment yet